Key result
High BMI-attributable deaths from hypertension-related CKD rose from 36,476 in 1990 to 179,788 in 2021 (ASMR 1.09 to 2.19 per 100,000; EAPC 4.22%), projected to reach 4.44 per 100,000 by 2050.
Why the study?
High body mass index exacerbates hypertension-related kidney injury, but the global burden of hypertension-related chronic kidney disease attributable to high BMI remains poorly characterized.
Observational
Yes
The global mortality and disability burden of hypertension-related chronic kidney disease attributable to high BMI has more than doubled between 1990 and 2021 and is projected to continue rising steeply through 2050, underscoring the urgent need for integrated obesity prevention and hypertension control.
Answers are grounded in this paper and cite their sources.
Rising high BMI-attributable hypertensive CKD mortality warrants prevention focus; leaves open whether interventions alter 2050 projections.
Chronic kidney disease (CKD) affects approximately 9.1% of the global population, equivalent to approximately 843 million individuals as of 2021, with hypertension (HTN) as a major contributor. High body mass index (BMI) exacerbates HTN-related kidney injury, but the global burden of HTN-related CKD attributable to high BMI remains poorly characterized. Using data from the Global Burden of Disease (GBD) 2021 study for 1990-2021, we estimated attributable deaths, disability-adjusted life years (DALYs), the age-standardized mortality rate (ASMR), and the age-standardized disability-adjusted life-year rate (ASDR). Temporal trends were assessed using the estimated annual percentage change (EAPC), and a Bayesian age-period-cohort model was used to project rates to 2050. Attributable deaths increased from 36,476 in 1990 to 179,788 in 2021, and DALYs increased from 1.01 million to 4.26 million. ASMR increased from 1.09 to 2.19 per 100,000 (EAPC, 4.22%), and ASDR increased from 26.04 to 50.11 per 100,000 (EAPC, 3.63%). Central Sub-Saharan Africa had the highest ASMR (7.66 per 100,000), whereas High-income North America had the fastest increase in ASMR (EAPC, 5.63%). ASMR and ASDR were higher in men than in women. Death counts peaked at ages 85-89 years in both sexes, whereas DALYs peaked at ages 60-64 years in men and 65-69 years in women. Crude rates were higher in populations with a higher sociodemographic index (SDI), whereas the relative burden became more concentrated in lower-SDI populations; concentration indices changed from -0.10 to -0.17 for deaths and from -0.06 to -0.08 for DALYs. By 2050, ASMR is projected to reach 4.44 per 100,000 (95% credible interval [CI], 3.70-5.20), and ASDR is projected to reach 77.15 per 100,000 (95% CI, 1.81-152.49). The high BMI-attributable burden of HTN-related CKD is increasing and remains unequally distributed. These findings support integrated obesity prevention and hypertension control, with priority given to high-risk regions and older adults.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted an observational in Hypertension-related chronic kidney disease (ICD-10 codes N18-N19). High body mass index (BMI >=25 kg/m2) vs. Theoretical minimum risk exposure level (BMI 20-25 kg/m2) was evaluated on Attributable deaths, disability-adjusted life years (DALYs), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR) for hypertension-related CKD (p=<0.05). High BMI-attributable deaths from hypertension-related CKD rose from 36,476 in 1990 to 179,788 in 2021 (ASMR 1.09 to 2.19 per 100,000; EAPC 4.22%), projected to reach 4.44 per 100,000 by 2050.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: